Research programme: small molecule therapeutics - Janssen Biotech/Nuevolution

Drug Profile

Research programme: small molecule therapeutics - Janssen Biotech/Nuevolution

Latest Information Update: 09 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nuevolution
  • Developer Janssen Biotech; Nuevolution
  • Class Anti-infectives; Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Infections; Inflammation

Most Recent Events

  • 04 Jan 2018 Janssen Biotech excercise option to in-license small molecule therapies for Infections
  • 19 Oct 2015 Nuevolution and Janssen Biotech agree to co-develop small molecule therapies in Denmark for Cancer, Infectious and Inflammatory diseases
  • 19 Oct 2015 Early research in Cancer in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top